Skip to search formSkip to main contentSkip to account menu

RG7388

Known as: RG-7388 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

IdasanutlinPyrrolidinespara-Aminobenzoates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
3395 An Injectable Sulfonated Reversible Thermal Gel for Controlled and Localized Delivery of Vascular Endothelial Growth Factor to Promote Cardiac Protection After a Myocardial Infarction
OBJECTIVES/SPECIFIC AIMS: This study aims to evaluate an injectable sulfonated reserve thermal gel (SPSHU-PNIPAM) for angiogenic… 
2017
2017
Abstract P3-07-21: Cytotoxic potential of the RG7388 MDM2-p53 binding antagonist and the GSK2830371 WIP1 inhibitor on MX-1 and MCF-7 human breast cancer cells
Background The tumor suppressor p53 is a central hub in molecular signaling pathways that control the integrity of the human… 
2016
2016
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans
Abstract 1. Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer. The… 
2016
2016
Fortifying p53 – beyond Mdm2 inhibitors
The tumor suppressor p53 is mutated in roughly 50% of all human malignancies. However, in the other 50% of tumors which retain… 
2015
2015
BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms
Acute myeloid leukemia (AML) is primarily treated with chemotherapy, but the 5-year survival rate has only marginally increased… 
2015
2015
Abstract 1614: Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma
Curative therapy for childhood sarcoma presents challenges when complete resection is not possible. Ionizing radiation (XRT) is… 
Highly Cited
2014
Highly Cited
2014
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
2014
2014
Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)
Background: Acute myeloid leukemia (AML) is characterized by the clonal expansion of immature myeloid cells. AML is treated… 
2014
2014
Abstract 5505: Synergistic anticancer activity of clinical stage, non-genotoxic apoptosis inducing agents RG7388 (MDM2 antagonist) and ABT-199 (GDC-0199, BCL2 inhibitor) in p53 wild-type AML tumor…
MDM2, the most prominent natural inhibitor of the p53 tumor suppressor pathway, and BCL2, an anti-apoptotic regulator and… 
2014
2014
Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity
Introduction: Obinutuzumab (GA101) is a novel glycoengineered type II, anti-CD20 monoclonal antibody that strongly induces direct… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)